AmantadineConstipation following off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2019年 / 1760卷 / 1期

关键词：

D O I：

10.1007/s40278-019-64179-8

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：20 / 20

相关论文

共 50 条

[1] RituximabPancytopenia following off-label use: case report
[J]. Reactions Weekly, 2020, 1807 (1) : 176 - 176
[2] FavipiravirNephrotoxicity following off-label use: case report
[J]. Reactions Weekly, 2022, 1929 (1) : 283 - 283
[3] DexamethasoneHyperglycaemia following off-label use: case report
[J]. Reactions Weekly, 2022, 1896 (1) : 173 - 173
[4] DexamfetamineHypertension following off-label use: case report
[J]. Reactions Weekly, 2021, 1883 (1) : 150 - 150
[5] NivolumabFever following off-label use: case report
[J]. Reactions Weekly, 2016, 1601 (1) : 186 - 186
[6] MirtazapineTachyphylaxis following off-label use: case report
[J]. Reactions Weekly, 2018, 1703 (1) : 182 - 182
[7] TocilizumabAnaphylaxis following off-label use: case report
[J]. Reactions Weekly, 2021, 1865 (1) : 397 - 397
[8] RivoceranibNeurotoxicity following an off-label use: case report
[J]. Reactions Weekly, 2018, 1702 (1) : 232 - 232
[9] MethotrexateSteatohepatitis following off-label use: case report
[J]. Reactions Weekly, 2019, 1768 (1) : 225 - 225
[10] AzacitidineDiarrhoea following off-label use: case report
[J]. Reactions Weekly, 2019, 1736 (1) : 48 - 48

← 1 2 3 4 5 →